Professional Documents
Culture Documents
A DISEASE CHARACTERIZED BY: LOW BONE MASS MICRO-ARCHITECTURAL DETERIORATION OF THE BONE TISSUE LEADING TO: ENHANCED BONE FRAGILITY INCREASE IN FRACTURE RISK
Loss of trabecular plates ( right) results in weakened bone structure significantly increasing risk of fractures.
Epidemiology
Disorder of postmenopausal women of northern European descent Increase in the incidence related to decreasing physical activity Over 27 million or 1of 3 women are affected with osteoporosis Over 5 million or 1of 5 men are affected with osteoporosis.
Fractures
1.5 million fx/yr 300,000 hip
700,000 vertebral
250,000 wrist
Vertebra Fractures
Hip Fractures
Impact
Chronic pain Height loss Kyphosis Decreased selfesteem Restrictive lung dx Constipation, abdominal pain Depression
Risk Factors
ACTIVE RISK FACTORS
DRUGS MALABSORPTION - Any cause: Medical or Surgical ONGOING ALCOHOL ABUSE HYPOGONADISM CHRONIC IMMOBILITY CHRONIC DISEASE
Risk Factors
INACTIVE RISK FACTORS
Classification
Primary
Postmenopausal osteoporosis (type I) Caused by lack of estrogen Causes PTH to over stimulate osteoclasts Excessive loss of trabecular bone Age-associated osteoporosis (type II) Bone loss due to increased bone turnover Malabsorption Mineral and vitamin deficiency Secondary
Secondary Osteoporosis
Disease states
Acromegaly Addisons disease Amyloidosis Anorexia COPD Hemochromatosis Hyperparathyroidism Lymphoma and leukemia Malabsorption states Multiple myeloma Multiple sclerosis Rheumatoid arthritis Sarcoidosis
Lithium
Normal: T score above 1 Osteopenia: T score between 1 and 2.5 Osteoporosis: T score at or below 2.5 Severe osteoporosis: T score 2.5 or lower in the presence of 1 or more fractures
ULTRASOUND
Underestimation of BMD
Need to establish standard for comparability of different devices and anatomic sites
Moderate Risk
T score 1.5 to 2.0 -------Treat if other risk factors are present
Low Risk
T score above 1.5 --------Check again in 1-2 years
When to Retest
Repeat testing in 2 yrs additional bone loss response to treatment More frequent testing if: glucocorticoid therapy for more than 3 years evidence of a secondary cause of osteoporosis
Bone Markers
Serum osteocalcin, procollagen I carboxyterminal propeptide, procollagen type I Nterminal propeptide, N and C-telopeptides
Treatment
Preventive Measures
Prevention of Bone Loss
Calcium Requirements
NO FIRM CONCLUSIONS MALES 11 - 18 YEARS
FEMALES 11 1 8 YEARS ADULTS (MALE AND FEMALE) LACTATION OSTEOPOROSIS
U.K.
1000
800
700
1250 1000
Sources of Calcium
FOOD
MILK - WHOLE MILK - SEMISKIMMED MILK - SKIMMED YOGHURT CHEDDAR CHEESE COTTEGE CHEESE ICE-CREAM SARD DIINES (with bones) ORANGE WHITE BREAD BAKED BEANS
SERVING SIZE
1 GLASS (190ML) 1 GLASS (190ML) 1 GLASS (190ML) 1 POT (150g) S MALL PIECE (30g) 2 TABLESPOONS 2 SCOOPS 2 CAN NED 1 MEDIUM 2 SLICES 3 TABLESPOONS
CALCIUM(mg)
225 231 236 225 216 58 156 230 75 72 64
ERT
Advantages Increases bone density (15%) and decreases risk of fracture (25%) Relief of hot flashes, vaginal dryness Decreases LDL, increases HDL Prevention of Alzheimers disease Relatively inexpensive
Disadvantages
Accelerated bone loss after stopping Increased risk of uterine ca (if unopposed) Increased risk of thromboembolic events Possible increased risk of breast cancer Side effects: breast tenderness, breakthrough bleeding Increased risk of coronary events in women with known CAD in first year of use (HERS trial)
SERMS
Advantages
Increases bone density (2%) and decreases fracture risk (30%) No stimulation of breast or endometrial tissue No need for progestin in women with uterus Decrease LDL
Disadvantages
Increased risk of thromboembolic events Doesnt treat postmenopausal sx May increase hot flashes No effect on HDL $60.90/30 day supply
Bisphosphonates
Approved agents Alendronate (Fosamax), Risedronate (Actonel)
Indication Approved for prevention and treatment of osteoporosis including steroid-induced osteoporosis
Mechanism Bind to hydroxappetite at sites of active bone resorption inhibiting osteoclast function Dose Prevention Alendronate 5mg qd or 35mg qweek Risedronate 5mg qd or 30mg qweek Treatment Alendronate 10mg qd or 70mg qweek Risedronate 5mg qd or 30mg qweeek
Bisphosphonates
Take first thing in am, no food or meds for 30 minutes Take with 8oz glass of water Dont lie down for at least 30 minutes Separate Ca, Al, and Mg containing meds by at least 4 hours
Bisphosphonates
Advantages
Increases BMD by 1-4%, decreases fracture risk by 41-44% No increased risk of breast, uterine ca or thromboembolic events Weekly dosing
Disadvantages
Risk of gastrointestinal sx Cost $61.20/30 day supply Complex dosing instructions Contraindicated in ESRD; need to adjust dose according to creatinine clearance
Calcitonin
Indication: Treatment only
Advantage May provide analgesic effect on bone pain associated with fractures Disadvantage Inconsistent effects on BMD and fracture risk
Parathyroid Hormone
Daily SC injections of 40mcg of PTH increased BMD by 9-13% and decreased risk of vertebral fractures by 65 to 69 % Side effects: Occasional headache and nausea Pending FDA approval
NEJM 2001;344:1434-41.